B
ENGN icon

Braidwell’s enGene Therapeutics ENGN Stock Holding History

Braidwell’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7M Sell
2,456,870
-674,449
-22% -$6M 0.56% 60
2025
Q4 		$28.3M Buy
3,131,319
+865,000
+38% +$6.93M 0.9% 43
2025
Q3 		$15.5M Buy
+2,266,319
New +$10.3M 0.46% 53

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Braidwell's ENGN Position: Q1 2026 in Review

Braidwell reduced its enGene Therapeutics (ENGN) stake by 22% in Q1 2026, selling an estimated $6M and leaving 2,456,870 shares worth $16.7M. The position accounts for 0.56% of the portfolio, ranked #60.

Braidwell first reported a position in ENGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $28.3M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Braidwell held 2,456,870 shares of enGene Therapeutics worth $16.7M as of Q1 2026.
  • Braidwell sold 674,449 enGene Therapeutics shares in Q1 2026, an estimated $6M.
  • enGene Therapeutics made up 0.56% of Braidwell's portfolio in Q1 2026, its #60 holding.
  • Braidwell first reported a position in enGene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Braidwell's enGene Therapeutics position peaked at $28.3M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.